MTPA Gets Orphan Drug Exclusivity for Radicava ORS

MTPA Gets Orphan Drug Exclusivity for Radicava ORS

By, Admin 10 April 2024

Mitsubishi Tanabe Pharma America gets US FDA orphan drug exclusivity for Radicava ORS

Overview

Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced that the US Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for Radicava ORS (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lat eral sclerosis (ALS). The FDA’s Orphan Drug programme is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the US Previously, the FDA granted Radicava ORS Priority Review and Fast Track designations.

Behind Approval 

  • The FDA recognized ODE for Radicava ORS because it provides a clinically superior option for patients due to its oral suspension route of administration that can help reduce the burden patients face with intravenous (IV) administration of previously approved Radicava (edaravone).
  • Radicava ORS is self-administered, can be taken orally or via feeding tube, comes in a portable bottle with an oral dosing syringe and no need for patients to refrigerate or reconstitute before taking. 
  • With appropriate instruction from a healthcare provider (HCP), Radicava ORS may take only a few minutes to administer on treatment days and should be taken in the morning after overnight fasting.

Words from Expert

  • “I’m thrilled at the FDA’s recognition of ODE to Radicava ORS,” said Stanley H. Appel, MD, Houston Methodist Stanley H. Appel Department of Neurology. 
  • “This comes at a critical time in the ALS treatment landscape and helps ensure that our patients and HCPs have a treatment option validated for several years, including by the pivotal phase 3 clinical trial.”

Phase 3 Study

  • The US approval of Radicava (edaravone) was based on the pivotal phase 3 study (Study 19 or MCI186-19), in which Radicava was shown to slow the loss of physical function by 33 per cent in 68 patients vs. placebo (n=66 patients), measured over a 24-week time period by the ALS Functional Rating Scale-Revised (ALSFRS-R). 
  • On average, patients on Radicava lost 2.49 fewer points on the ALSFRS-R vs. those in the placebo arm (p=0.0013). 
  • Radicava ORS offers the same efficacy as Radicava in a different formulation. 
  • The safety profile of Radicava was demonstrated in pooled placebo-controlled trials in which 184 patients with ALS were administered Radicava (60 mg) in 24-week treatment cycles. 
  • The safety profile of Radicava ORS was demonstrated in a 6-month, phase 3, open-label clinical trial in 185 patients.

Words from CEO: ALS Association

  • “We recognize the profound impact that an oral formulation has on the ALS community, in part by offering a less burdensome option for people living with ALS,” said Calaneet Balas, president & CEO, ALS Association. 
  • “We thank Mitsubishi Tanabe Pharma America for continuing their efforts to help provide treatments to people living with ALS.”
  • Treatment previously done
  • To date, in the US, over 14,600 people living with ALS have been treated with Radicava and Radicava ORS and has been prescribed by over 2,300 HCPs. 
  • Both formulations are supported by a robust set of data from multiple clinical trials, post-hoc analysis and real-world evidence (RWE) studies evaluating the efficacy and safety. 
  • These results have been published in over 40 peer-reviewed articles.

FDA Approvals 

  • The US Food and Drug Administration (FDA) approved Radicava (edaravone) on May 5, 2017, and the oral formulation Radicava ORS (edaravone) on May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS). 
  • In 2024, the FDA recognized Radicava ORS with Orphan Drug Exclusivity based on the major contribution to patient care of the innovative oral formulation. 
  • Radicava is administered in 28-day cycles by intravenous (IV) infusion. It takes 60 minutes to receive each 60 mg dose. 
  • For the initial cycle, the treatment is infused daily for 14 consecutive days, followed by a two-week drug-free period. 
  • All cycles thereafter are infused daily for 10 days within a 14-day period, followed by a two-week drug-free period. 
  • Radicava ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle. 
  • For subsequent treatment cycles, Radicava ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. 
  • Radicava ORS should be taken in the morning after overnight fasting. 
  • Patients should not eat or drink (except water) within one hour after taking Radicava ORS.

Edaravone

  • Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the US by Mitsubishi Tanabe Pharma America, Inc. (MTPA).
  • The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. 
  • In 2015, edaravone was approved as Radicut for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021) and Brazil (February 2024). 
  • Marketing authorization for Radicava Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and Radicut Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. 
  • To date, in the US, Radicava and Radicava ORS have been used to treat over 14,600 people with ALS, with over 1.8-million days of therapy, and have been prescribed by over 2,300 HCPs.

About MTPA

  • Based in Jersey City, New Jersey, Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). 
  • It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America.
  • Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. 
  • MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!